(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Xenon Pharmaceuticals's revenue in 2026 is $0.On average, 20 Wall Street analysts forecast XENE's revenue for 2026 to be $247,270,477, with the lowest XENE revenue forecast at $0, and the highest XENE revenue forecast at $2,295,323,485. On average, 21 Wall Street analysts forecast XENE's revenue for 2027 to be $4,727,912,051, with the lowest XENE revenue forecast at $0, and the highest XENE revenue forecast at $17,759,394,846.
In 2028, XENE is forecast to generate $25,864,801,214 in revenue, with the lowest revenue forecast at $11,908,229,105 and the highest revenue forecast at $78,560,092,485.